Your browser doesn't support javascript.
The Effect of Ivermectin on Cases of COVID-19.
Annie, Frank H; Campbell, James; Searls, Lauren; Amos, Jessica.
  • Annie FH; Charleston Area Medical Center Institute for Academic Medicine, 3200 MacCorkle Ave. SE, Charleston, WV 25304, United States of America. Electronic address: Frank.H.Annie@camc.org.
  • Campbell J; Department of Internal Medicine, West Virginia University, Charleston Division, Charleston Area Medical Center Institute for Academic Medicine, United States of America.
  • Searls L; Department of Internal Medicine, West Virginia University, Charleston Division, Charleston Area Medical Center Institute for Academic Medicine, United States of America.
  • Amos J; Department of Internal Medicine, West Virginia University, Charleston Division, Charleston Area Medical Center Institute for Academic Medicine, United States of America.
Cardiovasc Revasc Med ; 44: 98-100, 2022 11.
Article in English | MEDLINE | ID: covidwho-1894843
ABSTRACT
Ivermectin is an antiviral agent that has historically had a wide variety of uses. Recently, it has gained popularity in the mainstream media for use in treating and preventing COVID-19 infection, prompting high sales in veterinary grade Ivermectin. Studies are increasingly looking at Ivermectin as a possible agent for prevention and treatment of COVID-19, however further information is needed to assess efficacy and safety. Our project aimed to evaluate mortality differences in patients with COVID-19 infection who were prescribed Ivermectin vs. those not prescribed Ivermectin. Adult patients with active COVID-19 infection who were not prescribed Ivermectin (n = 797,285 Outpatient, n = 481,705 Inpatient, and n = 58,050 Intensive care unit), and those prescribed Ivermectin (n = 804 Outpatient, n = 1774 Inpatient, and n = 107 Intensive care unit) were evaluated. The cohorts were then evaluated for mortality comparing patients prescribed Ivermectin and those not prescribed Ivermectin in the Outpatient (7.7 % vs 2.2 %, P < 0.001), Inpatient not requiring Intensive Care (15.6 % vs 7.2 %, P ≤ 0.001), and Intensive care (20.6 % vs 19.6 %, P = 0.86) treatment settings.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Ivermectin / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Humans Language: English Journal: Cardiovasc Revasc Med Journal subject: Vascular Diseases / Cardiology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Ivermectin / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Adult / Humans Language: English Journal: Cardiovasc Revasc Med Journal subject: Vascular Diseases / Cardiology Year: 2022 Document Type: Article